Lim S, Groneberg D, Fischer A, Oates T, Caramori G, Mattos W, Adcock I, Barnes P J, Chung K F
Department of Thoracic Medicine, National Heart and Lung Institute, Imperial College School of Medicine, London, United Kingdom.
Am J Respir Crit Care Med. 2000 Nov;162(5):1912-8. doi: 10.1164/ajrccm.162.5.9909081.
Heme oxygenase (HO) is considered to be an antioxidant enzyme that catabolizes heme to produce carbon monoxide (CO) and biliverdin. We determined the expression and distribution of HO-1 and HO-2, two isoenzymes of HO, in the airways of patients with asthma, and determined the effect of inhaled corticosteroid therapy. Immunostaining for both enzymes was widely distributed in the airways' submucosa, particularly in airway epithelium and submucosal macrophages (CD68(+)) as determined by double immunostaining. There was no difference in intensity and extent of staining in biopsies from normal subjects (n = 10) and subjects with asthma (n = 10). Following 1 mo of treatment with inhaled corticosteroids (budesonide 1,600 microg/d), there was no significant change in the expression and distribution of either HO-1 or HO-2 in the airways' submucosa in eight subjects with mild asthma, despite a significant reduction in airway eosinophils and a reduction in bronchial responsiveness to methacholine. Levels of exhaled nitric oxide were significantly reduced, but exhaled CO levels remained unchanged by the treatment. Treatment with a placebo inhaler (n = 8) had no effects on these parameters. Thus, both HO-1 and HO-2 are extensively distributed equally in normal subjects and subjects with asthma, and are not modulated by inhaled corticosteroid therapy in subjects with asthma. HO may be an important endogenous antioxidant enzyme.
血红素加氧酶(HO)被认为是一种抗氧化酶,可催化血红素分解产生一氧化碳(CO)和胆绿素。我们测定了HO的两种同工酶HO-1和HO-2在哮喘患者气道中的表达和分布,并确定了吸入性糖皮质激素治疗的效果。通过双重免疫染色确定,这两种酶的免疫染色广泛分布于气道黏膜下层,特别是气道上皮和黏膜下巨噬细胞(CD68(+))。正常受试者(n = 10)和哮喘患者(n = 10)活检标本的染色强度和范围没有差异。在8例轻度哮喘患者中,吸入糖皮质激素(布地奈德1600μg/d)治疗1个月后,气道黏膜下层HO-1或HO-2的表达和分布没有显著变化,尽管气道嗜酸性粒细胞显著减少,对乙酰甲胆碱的支气管反应性降低。呼出一氧化氮水平显著降低,但呼出CO水平在治疗后保持不变。使用安慰剂吸入器治疗(n = 8)对这些参数没有影响。因此,HO-1和HO-2在正常受试者和哮喘患者中均广泛且均匀分布,并且在哮喘患者中不受吸入性糖皮质激素治疗的调节。HO可能是一种重要的内源性抗氧化酶。